Genmab Revenue and Competitors

Claim your profile

Copenhagen V, Denmark

Location

$204.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Genmab's estimated annual revenue is currently $7.9B per year.(i)
  • Genmab received $10.0M in venture funding in October 2014.
  • Genmab's estimated revenue per employee is $4,094,203
  • Genmab's total funding is $204.3M.
  • Genmab's current valuation is $23.5B. (January 2022)

Employee Data

  • Genmab has 1932 Employees.(i)
  • Genmab grew their employee count by 45% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7910M193245%$204.3MN/A
#2
$31.9M20623%N/AN/A
#3
$3.4M88123%$85.7MN/A
#4
$13.2M39-83%$263.3MN/A
#5
$16.1M10416%N/AN/A
#6
$2.6M1755%N/AN/A
#7
$8.7M56409%N/AN/A

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Disclaimer: bit.ly/GENDisclaimer

keywords:N/A

$204.3M

Total Funding

1932

Number of Employees

$7.9B

Revenue (est)

45%

Employee Growth %

$23.5B

Valuation

N/A

Accelerator

Genmab News

2022-04-06 - AbbVie and Genmab Announce Topline Results for ...

Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. ... To develop and deliver novel...

2022-04-06 - Genmab and AbbVie prep filings for lymphoma bispecific -

Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to...

2022-04-06 - Sanofi, AbbVie and Genmab Celebrate Mid-Phase Trial Wins

AbbVie and Genmab are co-developing epcoritamab as part of the companies' broader oncology collaboration deal. "Together with our partner,...

2019-09-08 - Tempus, Genmab Enter Oncology Biomarker Collaboration

Precision medicine company Tempus, and antibody therapeutics company Genmab announced have announced a strategic collaboration that ...

Genmab Funding

DateAmountRoundLead InvestorsReference
2014-10-27$10.0MUndisclosedJanssen Biotech IncArticle

Genmab Executives


NameTitle
Jan van de WinkelCEO/President
David EatwellExecutive Vice President & Chief Financial Officer
Judith KlimovskyExecutive Vice President & Chief Development Officer
Anthony PaganoChief Financial Officer
Tahamtan AhmadiCMO EVP Head of Experimental Medicine
Denise MigliaccioExecutive Assistant to Chief Operating Officer
Judith KlimovskyEVP& Chief Development Officer
Kay BehnkeCISO
Michelle PleiterSenior Executive Assistant to the CEO
Diane SchraubExecutive Assistant to Anthony Pagano, CFO Genmab
Jan VanPresident & Chief Executive Officer
Jan van de WinkelCEO/President
David EatwellExecutive Vice President & Chief Financial Officer
Birgitte StephensenSVP Legal/IPR
Rachel GravesenSenior Vice President, Investor Relations and Communications
Martine van VugtSVP Strategic Initiatives
Judith KlimovskyExecutive Vice President & Chief Development Officer
Michael BauerSenior Vice President, Head of Operations R&D
Christine ZettlemoyerSVP/ Global Head
Maryanne MccarthyVice President, Head of Alliance Management
Theodora SalcedoVP & Head Non Clinical Safety/Toxicology
Steve BryantVice President, Head of Global Business Development
Scott CenciSVP, Information Technology and Digital
Tahamtan AhmadiCMO EVP Head of Experimental Medicine
Rick JanssonVice President
Melissa ThomasVP, Program Development Lead
A Kate SasserSVP, Global Head of Translational Research and Precision Medicine, Research Ops, and Lab Management
Ron GraybillVice President, Market Access
John KeatingSenior Vice President, Global Commercialization
Julie BlaedelVice President Global Medical Affairs
Rima Bawarshi NassarVice President, Head of Global Regulatory Affairs
Gigi AtallaVice President, Global head of drug safety
Brad BaileySenior Vice President & General Manager
Javier PintadoVice President, Global Marketing
Judith KlimovskyEVP& Chief Development Officer
Dennis NielsenVP, Head of Procurement
David SatijnVice President, New Antibody Products
Judith OprinsVice President, Operations & Resource Management
Gitte KnudsenVice President, Head of Legal, Attorney-at-Law
Janine SchuurmanSenior Vice President, Head Antibody Research & Technology
Jesper ValbjørnVice President CMC
Claudia CorradoVice President, Medical, Hematology
Leslie AmendolaVP, US Marketing & Sales
Claire BlanchetteVice President, Compound Development Team Leader
Michael MaldonadoVP, Head of Global Rewards
Cristian LizzioVice President, Global HR Operations & Systems
Anthony BerlocoVP, Controller Genmab
Vibeke DidriksenVP, Global Head of Diversity, Equity and Inclusion
Jan VanPresident & Chief Executive Officer
Suzana CoutoVice President, Head of Pathology
Riemke Dijkhuizen-RadersmaVice President, Head of Global Portfolio & Project Management